心力衰竭的药剂师指导的医疗治疗:初级保健中的影响分析
Markus Schichtel1, Stephen Barclay2, Helena Papworth3
1Department of Public Health and Primary Care, University of Cambridge, Cambridge, England, UK ms2591@cam.ac.uk.
BMJ open quality
|September 1, 2025
概括
药剂师主导的心力衰竭 (HF) 管理模式显著增加了初级保健中指导性医疗治疗 (GDMT) 率. 这种方法减少了医疗费用,医生工作量,死亡率和住院时间,改善了患者的生活质量.
科学领域:
- 心脏病学和初级护理医学
- 由药剂师领导的健康干预措施
- 医疗服务研究
背景情况:
- 针对心力衰竭的指导医疗 (GDMT) 改善了结果,但在英国的初级保健中未得到充分使用.
- 医生能力有限和HF负担增加需要创新的护理模式.
- 低于最佳的GDMT有助于预防死亡率和住院率.
研究的目的:
- 评估新型药剂师主导的GDMT模型,以优化英国初级保健中的HF护理.
- 评估对GDMT率,医疗费用,全科医生工作量,死亡率和生活质量的影响.
主要方法:
- 一个多站点的定量影响分析,涉及237名低风险的HF患者.
- 使用HF事件强度评分来识别患者.
- 基线,6个月和2年的最佳GDMT率,成本和工作量进行比较.
主要成果:
- 最佳GDMT从基线时的17. 7% 增加到6个月后的76. 5% 和2年后的94. 5%.
- 医生工作量减少了36.6% (6个月) 和42.1% (2年);医疗费用减少了18.4% (6个月) 和20.3% (2年).
- 小组分析显示心血管死亡率降低 (20. 8%),住院病例减少 (34. 8%) 和生活质量改善 (5. 31 KCQ评分).
结论:
- 药剂师主导的GDMT优化显著提高了低风险HF患者的治疗率.
- 这种模式有效地降低了医疗费用和全科医生的工作量.
- 这种方法显示出广泛实施的潜力,以改善HF患者的治疗结果和管理工作负载压力.
相关概念视频
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:21Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505